跳至主要内容
临床试验/NCT01707368
NCT01707368已完成不适用

Course of Psoriasis During Long Term Treatment With Calcipotriol Plus Betamethasone in Gel Formulation

LEO Pharma1 个研究点 分布在 1 个国家目标入组 561 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
LEO Pharma
入组人数
561
试验地点
1
主要终点
The Course of Disease and Relapse Management During Treatment With Daivobet® Gel Under Consideration of Patient's Individual Application Habits Under Daily Use Conditions.

研究概览

简要总结

The purpose of this observational study is to document the course of disease and relapse management during treatment with Daivobet® Gel under consideration of patient's individual application habits under daily use conditions.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with light to moderate psoriasis vulgaris of trunk and extremities and treatment with Daivobet® Gel was planned anyway.
  • Minimum of 3 years diagnosed psoriasis vulgaris.

排除标准

  • Previous therapy with Daivobet® Gel
  • Systemic therapy of psoriasis vulgaris
  • Contraindications of Daivobet® Gel in the German package insert
  • people that are incapable to give free consent

研究组 & 干预措施

all eligible patients

Daivobet® Gel once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.

干预措施: Daivobet® Gel (Drug)

结局指标

主要结局

The Course of Disease and Relapse Management During Treatment With Daivobet® Gel Under Consideration of Patient's Individual Application Habits Under Daily Use Conditions.

时间窗: 1 year

Number of exacerbations and relapses during one year observation time

次要结局

  • PGA (Physician's Global Assessment of Psoriasis Vulgaris Severity)(1 year)
  • Side Effects(1 year)

研究者

发起方
LEO Pharma
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验